Cipla Limited — Gefitinib Exporter Profile
Indian Pharmaceutical Exporter · #1 for Gefitinib · $1.1M export value · DGFT Verified
Cipla Limited is the #1 Indian exporter of Gefitinib with $1.1M in export value and 21 verified shipments. Cipla Limited holds a 15.5% market share in Gefitinib exports across 3 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Gefitinib Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Gefitinib?
Cipla Limited exports Gefitinib to 3 countries. The largest destination is BRAZIL accounting for 51.5% of Cipla Limited's Gefitinib shipments, followed by IRAQ (40.2%) and AUSTRALIA (8.2%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Gefitinib from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLA BRASIL IMPORTADORA E | BRAZIL | $309.7K | 8 |
| THE MODERN CO | IRAQ | $300.0K | 6 |
| CIPLA BRASIL IMPORTADORA E DISTRIBUIDORA DE MEDICAMENTOS LTD | BRAZIL | $138.5K | 3 |
| CIPLA AUSTRALIA PTY LIMITED | AUSTRALIA | $50.0K | 1 |
| THE MODERN COMPANY FOR DRUGS INDUST | IRAQ | $50.0K | 1 |
| CIPLA AUSTRALIA PTY LTD, | AUSTRALIA | $16.3K | 1 |
| CIPLA AUSTRALIA PTY LTD | AUSTRALIA | $5.3K | 1 |
Cipla Limited supplies Gefitinib to 7 buyers globally. The largest buyer is CIPLA BRASIL IMPORTADORA E (BRAZIL), followed by THE MODERN CO (IRAQ) and CIPLA BRASIL IMPORTADORA E DISTRIBUIDORA DE MEDICAMENTOS LTD (BRAZIL). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Gefitinib Export Value and How Much Does Cipla Limited Contribute?
India exported $2.6M worth of Gefitinib through 297 shipments from 80 suppliers to 47 countries, serving 135 buyers globally. Cipla Limited contributes $1.1M to this total, accounting for 15.5% of India's Gefitinib exports. Cipla Limited ships Gefitinib to 3 countries through 7 buyers.
What Is the Average Shipment Value for Cipla Limited's Gefitinib Exports?
Cipla Limited's average Gefitinib shipment value is $50.0K per consignment, based on 21 shipments totaling $1.1M. The largest destination is BRAZIL (51.5% of Cipla Limited's Gefitinib exports).
How Does Cipla Limited Compare to Other Indian Gefitinib Exporters?
Cipla Limited ranks #1 among 80 Indian Gefitinib exporters with a 15.5% market share. The top 3 exporters are CIPLA LIMITED ($1.1M), NATCO PHARMA LIMITED ($500.0K), JODAS EXPOIM PRIVATE LIMITED ($395.7K). Cipla Limited processed 21 shipments to 3 destination countries.
What Gefitinib Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| GEFTICIP 250MG TABLET GEFITINIB 250MG TABLET PACK SIZE 3 X 10S | $150.0K | 3 |
| GEFTICIP 250MG TABLET GEFITINIB 250MG TABLETPACK SIZE 3 X 10S | $150.0K | 3 |
| TYKITICIP 250 MG TABLETS COMMERCIAL GEFITINIB 250 MG 442 PACKS X 3X10'S=13260 NOS | $138.5K | 3 |
| CIPLA GEFITINIB 250MG TABLETS GEFITINIB | $50.0K | 1 |
| TYKITICIP 250 MG TABLETS COMMERCIAL (GEFITINIB 250 MG) (442PACKS X 3X10'S=13260NOS) | $50.0K | 1 |
| GEFTICIP 250MG TABLET (GEFITINIB 250MG TABLET)PACK SIZE 3 X 10S | $50.0K | 1 |
| TYKITICIP 250 MG TABLETS COMMERCIAL (GEFITINIB 250 MG)(1380 PACKS X3X10S=41400 NOS) | $50.0K | 1 |
| TYKITICIP 250 MG TABLETS COMMERCIAL(GEFITINIB 250 MG) (1820 PACKS X 3X10S=54600 NOS) | $50.0K | 1 |
| TYKITICIP 250MG TABLETS (GEFITINIB 250MG | $45.9K | 1 |
| TYKITICIP 250 MG TABLETS COMMERCIAL (GEFITINIB 250 MG)(3 X 10'S X 480 =14400 NOS) | $29.8K | 1 |
Cipla Limited exports 15 distinct Gefitinib formulations including tablets, capsules, syrups, and combination drugs. The top formulation is GEFTICIP 250MG TABLET GEFITINIB 250MG TABLET PACK SIZE 3 X 1 with 3 shipments worth $150.0K.
Regulatory Requirements: Exporting Gefitinib to Key Markets
What Cipla Limited must comply with to export Gefitinib to its top destination countries
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Gefitinib Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | CIPLA LIMITED ★ | $1.1M | 21 | 3 | $50.0K |
| 2 | NATCO PHARMA LIMITED | $500.0K | 10 | 6 | $50.0K |
| 3 | JODAS EXPOIM PRIVATE LIMITED | $395.7K | 11 | 5 | $36.0K |
Cipla Limited ranks #1 among 80 Indian Gefitinib exporters. Average shipment value of $50.0K compared to the market average of $32.6K. The closest competitors by value are NATCO PHARMA LIMITED and JODAS EXPOIM PRIVATE LIMITED.
Which Indian Ports Ship Gefitinib Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 72 | 24.2% |
| SAHAR AIR | 56 | 18.9% |
| DELHI AIR CARGO ACC (INDEL4) | 34 | 11.4% |
| DELHI AIR | 25 | 8.4% |
| Bombay Air | 23 | 7.7% |
| AHEMDABAD AIR | 11 | 3.7% |
| Delhi Air | 10 | 3.4% |
| HYDERABAD AIR | 10 | 3.4% |
Geopolitical & Trade Policy Impact on Cipla Limited's Gefitinib Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Gefitinib, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Gefitinib — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Gefitinib shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 21 individual customs records matching Cipla Limited exporting Gefitinib, covering 15 formulations to 3 countries via 7 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 47+ countries, 135+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Gefitinib Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Gefitinib exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Gefitinib Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Gefitinib. For current shipment-level data, contact TransData Nexus.